Inactive Instrument

Urovant Sciences Ltd.

UROV

BMG9381B1081

Biotechnology & Medical Research

Urovant Sciences Ltd. Names James Robinson as CEO

June 18, 2020 at 09:12 pm

Urovant Sciences Ltd. named James Robinson as CEO. Mr. Robinson has deep experience in the urology and overactive bladder markets.

Latest news about Urovant Sciences Ltd.

Urovant Sciences and Pierre Fabre Médicament Enters into Exclusive License Agreement	05/07/22	CI
Urovant Sciences Ltd. Presents New Data from EMPOWUR Study, Advancing Knowledge of the Treatment of Overactive Bladder at the 2022 American Urological Association Meeting	15/05/22	CI
Urovant Sciences Presents Interim Data from Phase 2a Study of Investigational Novel Gene Therapy, URO-902, Supporting Safety, Tolerability, and Efficacy Endpoints	13/05/22	CI
Urovant Sciences Announces the Publication of A New, Post-Hoc Analysis of Data from the Phase 3 EMPOWUR Trial of GEMTESA 75 Mg in the International Journal of Clinical Practice	19/04/22	CI
Urovant Sciences Announces Management Changes	04/04/22	CI
Urovant Sciences Ltd. Announces Executive Changes	26/10/21	CI
Urovant Sciences Names Betzy Estrada as Executive VP and Chief Human Resources Officer	20/08/21	CI
Urovant Sciences to Present Key Data for GEMTESA® 75 Mg At the 2021 Annual Meeting of the American Urological Association	18/08/21	CI
Urovant Sciences Ltd.(NasdaqGS:UROV) dropped from S&P TMI Index	31/03/21	CI
Urovant Sciences Ltd. Announces Board Changes	29/03/21	CI
Urovant Sciences Ltd.(NasdaqGS:UROV) dropped from NASDAQ Composite Index	29/03/21	CI
Sumitovant Biopharma Ltd. completed the acquisition of the remaining 27.6% stake in Urovant Sciences Ltd..	28/03/21	CI
Transcript : Urovant Sciences Ltd. - Shareholder/Analyst Call	23/03/21
Urovant Sciences : Posts Wider Fiscal Q3 Net Loss	12/02/21	MT
Urovant Sciences Ltd. Reports Earnings Results for the Third Quarter Ended December 31, 2020	12/02/21	CI
Urovant Sciences : Safety Monitoring Board Recommends Phase 2a Trial of Urovant Sciences' URO-902	11/02/21	MT
Urovant Sciences Announces Progression of URO-902 Phase 2A Trial Following Positive Recommendation from the Data and Safety Monitoring Board	11/02/21	CI
Urovant Sciences Ltd. Announces Amendments to Sumitomo Loan Agreement	09/02/21	CI
Urovant Sciences : Gets FDA Nod For Overactive Bladder Drug Gemtesa -- Stock Up 3% After-Hours	23/12/20	MT
Urovant Sciences Announces U.S. FDA Approval of GEMTESA 75 mg Tablets for the Treatment of Patients with Overactive Bladder	23/12/20	CI
Urovant Sciences : Says Topline Data From Vibegron Study for Irritable Bowel Syndrome Failed to Meet Primary Endpoint	24/11/20	MT
Urovant Sciences Reports Topline Data from the Phase 2A Clinical Trial Evaluating Once-Daily Vibegron 75 Mg	24/11/20	CI
Urovant Sciences : Reports Positive Data From Study of Vibegron to Treat Overactive Bladder	19/11/20	MT
Urovant Sciences Announces Positive Clinical Efficacy and Safety Data from Vibegron Empowur Long Term Extension Study	19/11/20	CI
UROVANT SCIENCES : HC Wainwright Downgrades Urovant Sciences to Neutral From Buy; Price Target is $16.25	16/11/20	MT

Urovant Sciences Ltd. is a biopharmaceutical company. The Company is focused on developing and commercializing therapies for a range of urologic conditions. The Company's lead product, GEMTESA (vibegron), is an oral, once-daily (75 mg) small molecule beta-3 agonist for the treatment of adult patients with overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. GEMTESA is also being evaluated for the treatment of OAB in men with benign prostatic hyperplasia. The Company's second product candidate, URO-902, is a gene therapy being developed for patients with OAB who have failed oral pharmacologic therapy.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+9.83%	118B
REGENERON PHARMACEUTICALS, INC.	+10.80%	106B
BIONTECH SE	-10.84%	23.4B
ARGENX SE	-1.69%	22.1B
GENMAB A/S	-10.23%	18.34B
WUXI APPTEC CO., LTD.	-41.92%	16.59B
BEIGENE, LTD.	-15.11%	15.97B
NEUROCRINE BIOSCIENCES, INC.	+6.62%	14.03B
SAREPTA THERAPEUTICS, INC.	+17.53%	11.67B

Bio Therapeutic Drugs